Journal of Cancer Policy最新文献

{"title":"Manuscript title: Trends in consumption and expenditures of targeted anticancer therapies in Tunisia","authors":"Farah Allani ,&nbsp;Sarah Zerei ,&nbsp;Skander Daghfous ,&nbsp;Radhouane Mhidi ,&nbsp;Nadia Fenina ,&nbsp;Dora cherif","doi":"10.1016/j.jcpo.2026.100720","DOIUrl":"10.1016/j.jcpo.2026.100720","url":null,"abstract":"<div><h3>Background</h3><div>Targeted anticancer therapies have changed cancer care yet simultaneously imposed financial burdens on healthcare systems in Tunisia. This study aimed to analyze the national trends in consumption and expenditure of targeted anticancer therapies.</div></div><div><h3>Methods</h3><div>A retrospective analysis of national data from 2010 to 2021 was conducted to assess expenditure, consumption volume, therapeutic class distribution, and market authorization status.</div></div><div><h3>Results</h3><div>Over the study period, two distinct trends were observed in the use of targeted anticancer therapies. The volume number has increased markedly, with an increase in expenditures by 88% during the 2010–2017 period. Monoclonal antibodies dominated the market (70% of total spending in 2017). Then, between 2017 and 2020, the total expenditure decreased by 15% despite a 34% increase in unit consumption, and the market share of monoclonal antibodies (56%) and tyrosine kinase inhibitors (44%) became nearly comparable. These trends can be explained by the analysis of the number of market authorizations granted which increased during this period as well as the uptake of biosimilar and generics introduced in 2014 and the local manufacturing.</div></div><div><h3>Conclusion</h3><div>The Tunisian experience highlights the challenge of accessing targeted anticancer therapies while maintaining financial sustainability. Key strategies for ensuring sustainable and fair access to these innovative drugs include implementing pharmacoeconomic strategies, conducting continuous evaluations, introducing strategic market price revisions, price negotiations policies and promoting local manufacturing to ensure sustainable and equitable access to targeted anticancer therapies.</div></div><div><h3>Policy summary</h3><div>The growing use of targeted anticancer therapies in Tunisia has intensified financial pressures. This paper provides an analysis of the current national landscape of these drugs to inform policy solutions aimed at improving access and ensuring sustainability. Based on these findings, it proposes measures related to pricing, reimbursement, pharmacoeconomic evaluation, and the promotion of biosimilars and local manufacturing to support more sustainable and equitable access.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100720"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146259338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence on vaping e-cigarettes as a risk factor for cancer: A cautionary tale in flawed synthesis","authors":"Red Thaddeus D. Miguel,&nbsp;Isabella Steffensen","doi":"10.1016/j.jcpo.2025.100673","DOIUrl":"10.1016/j.jcpo.2025.100673","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100673"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing TELEMEDICINE adoption into European cancer care through the Joint Actions eCAN and eCAN+","authors":"Chloë Mbarushimana,&nbsp;Robbe Saesen,&nbsp;Victoria Leclercq,&nbsp;Marc Van den Bulcke,&nbsp;Marie Delnord","doi":"10.1016/j.jcpo.2025.100693","DOIUrl":"10.1016/j.jcpo.2025.100693","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100693"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THE IMPACT OF CANCER ON EMPLOYMENT AND INCOME: DO COASTAL INEQUALITIES EXIST?","authors":"A. Spencer ,&nbsp;B. Pickwell-Smith ,&nbsp;D. Nelson ,&nbsp;P. Mee ,&nbsp;C. Foster ,&nbsp;L. Calman ,&nbsp;B. Foster ,&nbsp;K. Spencer","doi":"10.1016/j.jcpo.2025.100686","DOIUrl":"10.1016/j.jcpo.2025.100686","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100686"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital outreach and public health: evaluating social media interventions on HPV-related cancers awareness and vaccine acceptance in Bosnia and Herzegovina","authors":"Družić Amil ,&nbsp;Hadžibeganović Amina ,&nbsp;Sokolović Emir ,&nbsp;Salković Naida ,&nbsp;Kapisazović Elma ,&nbsp;Velda Smajlbegović ,&nbsp;Hasanbegović Berisa ,&nbsp;Sokolović Selma ,&nbsp;Tinjak Enis ,&nbsp;Salčinović Asaf ,&nbsp;Eminović Meris ,&nbsp;Pašić Anes ,&nbsp;Timur Cerić ,&nbsp;Bešlija Semir","doi":"10.1016/j.jcpo.2025.100698","DOIUrl":"10.1016/j.jcpo.2025.100698","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100698"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactivity of A novel magainin peptide, QUB-2392, on acute myeloid leukaemia cell lines","authors":"Ruth Gyereh Dogwul ,&nbsp;Ajit Shah ,&nbsp;Zhanzhong Shi ,&nbsp;Xuesong Wen ,&nbsp;Dong Li ,&nbsp;Tianbao Chen ,&nbsp;Mei Zhou","doi":"10.1016/j.jcpo.2025.100687","DOIUrl":"10.1016/j.jcpo.2025.100687","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100687"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An examination of knowledge, awareness and practices towards breast cancer risk factors and early detection among females in the Fiji Islands","authors":"Carol Kartika Naidu ,&nbsp;Nicola Wiseman ,&nbsp;Belinda Chan ,&nbsp;Neil Harris","doi":"10.1016/j.jcpo.2026.100721","DOIUrl":"10.1016/j.jcpo.2026.100721","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to present a comprehensive examination of breast cancer awareness among women in Fiji. It was prompted by the alarmingly high rates of breast cancer in Fiji and the Pacific Islands. The goal was to enhance our understanding of women's knowledge, attitudes, and practices (KAP) regarding breast cancer in Fiji.</div></div><div><h3>Methods</h3><div>To achieve this, we conducted a cross-sectional KAP survey developed using the Breast Cancer Awareness Measures (BCAM) and surveyed over 250 women across Fiji who were aged 20 and above.</div></div><div><h3>Results</h3><div>The survey results revealed an overall low level of awareness concerning breast cancer signs and symptoms. Furthermore, a significant proportion of women had never undergone cancer screening and rarely or never performed breast self-checks. However, despite the infrequency of examinations, most women indicated they would seek medical attention if they detected a lump or noticed any changes in their breasts. Additionally, psychological barriers, including fear, emerged as significant barrier to seeking medical care.</div></div><div><h3>Conclusion</h3><div>In conclusion, this study highlights the pressing need for comprehensive educational programs and public health strategies aimed at addressing the low level of breast cancer awareness and the challenges associated with early detection among Fijian women</div></div><div><h3>Policy Summary</h3><div>The study's findings can inform the development of targeted interventions and public health strategies in the Fiji Islands that promote early detection and prevention of breast cancer, which are key to reducing the incidence and mortality rates of the disease.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100721"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146229075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-related out-of-pocket costs in advanced cancer patients in Spain: Functional dependence and socioeconomic inequalities","authors":"Alberto García-Martín ,&nbsp;Celia Sánchez-Gómez ,&nbsp;Susana Sáez-Gutiérrez ,&nbsp;Eduardo J. Fernández-Rodríguez","doi":"10.1016/j.jcpo.2026.100711","DOIUrl":"10.1016/j.jcpo.2026.100711","url":null,"abstract":"<div><h3>Background</h3><div>Advanced-stage cancer imposes a substantial economic burden on patients and families, even within universal public healthcare systems. Non-reimbursed direct costs—such as medications, parapharmacy products, and orthopaedic materials—pose a particularly severe impact on individuals with functional dependence and limited institutional support. This study focuses on the objective component of financial burden, operationalised as unreimbursed out-of-pocket (OOP) costs from a patient/household perspective.</div></div><div><h3>Methods</h3><div>A cross-sectional observational study was conducted at a public hospital in Spain between January 2022 and January 2024, including 201 patients with advanced-stage cancer. Socio-demographic, clinical, and economic data were collected through structured interviews, including annual out-of-pocket expenses for the previous 12 months (nominal euros, 2022–2024, without inflation adjustment), alongside functional assessments (Barthel Index, Lawton–Brody Scale, ECOG Performance Status, EQ-5D). Non-parametric tests (Mann–Whitney U and Kruskal–Wallis; α = 0.05) examined associations, and exploratory multivariate regression models were applied to adjust for functional and socioeconomic factors.</div></div><div><h3>Results</h3><div>In the previous year, 67.7 % of participants reported pharmacy or parapharmacy expenses, and 10 % spent more than €1200. Orthopaedic costs were incurred by 54.2 %, despite theoretical public coverage; 23.9 % spent more than €600. Functional impairment was frequent, with 38.3 % of patients presenting ECOG ≥ 3. Only 25.4 % received any financial support, while the majority reported none. Pharmacy-related expenses were significantly higher among patients with greater functional dependence and income reductions (p &lt; 0.05). Additional associations were found with marital status and pre-diagnosis income.</div></div><div><h3>Conclusion</h3><div>Unreimbursed out-of-pocket costs represent a major source of objective financial burden in advanced cancer, disproportionately affecting patients with functional dependence and reduced household income. Current co-payment exemptions insufficiently capture vulnerable profiles.</div></div><div><h3>Policy summary</h3><div>These findings support national (Spain’s Cancer Strategy 2021–2025) and European (Cancer Inequalities Registry) frameworks aimed at reducing social and economic inequalities in cancer care.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100711"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross sectional analysis of long-term overall survival among patients taking immune checkpoint inhibitor drugs","authors":"Alyson Haslam ,&nbsp;Timothée Olivier ,&nbsp;Vinay Prasad","doi":"10.1016/j.jcpo.2025.100669","DOIUrl":"10.1016/j.jcpo.2025.100669","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) have transformed the landscape of tumor therapy. Yet, little is known about the collective long-term survival from these therapies. We sought to characterize long-term survival.</div></div><div><h3>Methods</h3><div>In a cross-sectional analysis of US FDA oncology ICI drug approvals (2011–2023), we retrieved data from supporting registration trials. We examined the percentage of study participants surviving at 12-, 24-, 36-, and 60-months follow-up; the American Society of Clinical Oncology (ASCO) Value Framework Tail of the Curve calculation; and the correlation between the longest time with 10 % of patients still at-risk and the difference in the percentage of patients in each treatment group alive.</div></div><div><h3>Results</h3><div>Out of 88 included approvals, 20 (22.7 %) qualified for ASCO’s tail of the curve bonus. Twenty-seven studies (30.7 %) did not report OS at 12 months; 44 (50.0 %) did not report OS at 24 months; 60 (68.2 %) did not report OS at 36 months; and 78 (88.6 %) did not report OS at 60 months. We found no correlation between the last time that at least 10 % of patients were still at-risk and the difference in the percentage of patients in each group still alive at that time-point (R²=0.1; p = 0.30). Among 81 studies that reported an OS curve, the longest time with at least 10 % of participants at-risk was a median of 30 months. The median difference in survival was 8 %.</div></div><div><h3>Conclusions</h3><div>Few registration trials testing ICI oncology therapies report long-term overall survival data. The gathering and reporting of this information should be incentivized so that the value of these drugs for patients can be more readily assessed.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100669"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons learned from the support of the International Atomic Energy Agency, International Agency for Research on Cancer and World Health Organization to develop National Cancer Control Plans in low- and middle-income countries","authors":"Lisa Montel ,&nbsp;John Russell ,&nbsp;Issimouha Dille Mahamadou ,&nbsp;Mary Nyangasi ,&nbsp;Sharon Katai Kapambwe ,&nbsp;Alfred Karagu Maina ,&nbsp;Valerian Mwenda ,&nbsp;Andre Carvalho ,&nbsp;Geraldine Arias de Göbl ,&nbsp;Marianna Nobile ,&nbsp;Yannick Romero ,&nbsp;Mauricio Maza ,&nbsp;Lisa M. Stevens","doi":"10.1016/j.jcpo.2025.100652","DOIUrl":"10.1016/j.jcpo.2025.100652","url":null,"abstract":"<div><h3>Background</h3><div>The International Atomic Energy Agency (IAEA), International Agency for Research on Cancer (IARC) and World Health Organization (WHO) assist countries in building and strengthening their cancer control capacity. This support includes guidance to Member States to set priorities for national cancer control through the development and implementation of National Cancer Control Plans (NCCPs). Our aim was to identify the lessons learned from the support United Nations (UN) agencies provide to develop NCCPs in low- and middle-income countries (LMICs) to support the development of guidance.</div></div><div><h3>Methods</h3><div>We developed a questionnaire based on a review of the NCCP literature and conducted semi-structured interviews with 11 Member States that received UN agency support between 2020 and 2023 and five IAEA Programme Officers who coordinated UN support. We coded the transcripts inductively and performed a thematic analysis of the data.</div></div><div><h3>Results</h3><div>Three main themes were identified, each with their own barriers and enablers to develop NCCPs: coordination of NCCP development; method; and governance. We discuss each of these challenges and offer recommendations for Member States and UN agencies to further improve the development process of national cancer control strategies. We selected Kenya as a case study to show an example of good practice.</div></div><div><h3>Conclusion</h3><div>This paper complements a sister study conducted by the International Cancer Control Partnership which assessed challenges of developing NCCPs for countries that received a different type of support. Both studies contribute to the growing body of NCCP literature following the 2025 global review of NCCPs.</div></div><div><h3>Policy summary</h3><div>The lessons learned from the IAEA-IARC-WHO support to develop NCCPs will inform policies, programmes and practices in cancer control planning and implementation in LMICs, as well as the development of a common methodology for UN agencies to provide NCCP support.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100652"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145356399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}